HQL · Abrdn Life Sciences Investors

Know the company

Company overview

Abrdn Life Sciences Investors owns companies working across biotechnology and other life sciences. Its shareholder cash rests on an investment portfolio where product development and share-price results can outweigh ordinary dividend income.

Business: Healthcare equity CEF
Listing: HQL · XNYS
Reporting period: 2026-03-31
Dividend schedule: Quarterly

How the business works

Net investment income records dividends and interest after costs. Gains or losses in life-sciences holdings are separate, so a negative income figure cannot tell the whole story of a managed equity payment.

Abrdn Life Sciences Investors: financial report supporting reported earnings

Current company data

Latest reported earnings per share$-0.09Fund net investment income per common share; actual reporting period, not annualized · 2025-10-01 through 2026-03-31

Latest declared dividend$0.6200Quarterly; current regular payment checked 2026-09-11

Source dateSeptember 11, 2026Latest available source

Net asset value (NAV)

NAV per share$19.7600Sep 29, 2026

Market price$18.4900Sep 29, 2026

PREMIUM / DISCOUNT TO NAV6.43% discountCalculated from the displayed same-date values.

NAV is the fund's assets minus liabilities, divided by shares outstanding. All values are USD per share.

CEFConnect current common-share NAV and closing market price, both dated 2026-09-29. The published premium or discount agrees with the calculation within source rounding. Older audited NAV history remains unchanged.

NAV source · Market-price source

Return to company research